Thermo Fisher Scientific posts Q3 2026 earnings beat, launches Mayo Clinic partnership and raises 2026 guidance
Thermo Fisher Scientific reported third‑quarter 2026 revenue of $12.14 billion, up 9% year‑over‑year, and adjusted EPS of $6.68, up 15% YoY. The company completed the divestiture of its microbiology business and announced a new Precure partnership with the Mayo Clinic to combine data from more than one million patient samples. It also lifted its full‑year 2026 revenue guidance to $47.7‑$48.2 billion and EPS guidance to $25.13‑$25.43.
Why it matters
The earnings beat and higher guidance suggest stronger than expected demand and profitability, which could support a higher valuation for TMO (the company raised its 2026 revenue and EPS outlook, per the earnings call). The Mayo Clinic partnership may open new revenue streams in precision‑medicine services.
Key facts
- 1Q3 2026 revenue was $12.14 billion, a 9% increase YoY. stocktitan.net
- 2GAAP diluted EPS for Q3 2026 was $4.64, a 9% increase YoY. stocktitan.net
- 3Adjusted EPS for Q3 2026 was $6.68, a 15% increase YoY. stocktitan.net
- 4Organic revenue growth was 6% in the quarter. finance.yahoo.com
- 5Thermo Fisher completed the divestiture of its microbiology business during the quarter. stocktitan.net
- 6The company launched the Precure initiative with the Mayo Clinic to combine data from more than one million patient samples. stocktitan.net
Summary written by AlphAI AI Desk from 18 of 18 sources. Not investment advice. Figures are as stated by the linked sources.